/Investor DB

Pivotal Life Sciences — 2019 Investments

4 investments dated 2019 · listed companies and verified rows first · show all

Bolt Biotherapeuticsboltbio.comin𝕏NASDAQ: BOLTFeb 2019 · $54M

Bolt Biotherapeutics is a clinical-stage biotech company developing novel immunotherapies that leverage innate immune system mechanisms to treat cancer.

BiotechHealthtechMedical DevicesSan Francisco, US

Dr. Edgar G. Engleman(Founder)

Co-investorsPfizer Venture InvestmentsRA CapitalSamsara BioCapitalSofinnova VenturesVivo CapitalNan Fung Life Sciences+3 more

Fusion Pharmaceuticalsfusionpharma.comin𝕏Apr 2019 · $105M

Fusion Pharma develops targeted alpha therapeutics that link alpha-emitting medical isotopes to molecules targeting biomarkers on cancer cell surfaces to selectively kill tumor cells.

BiotechHealthtech

John Valliant(Founder)in

Co-investorsFACIT (Fight Against Cancer Innovation Trust)Genesys CapitalHealthCapLumira VenturesSeroba Life SciencesVenture Ontario+6 more

Seroba Life Sciencesseroba-lifesciences.cominApr 2019 · $105M

This page is a news post from Azafaros, a biopharmaceutical company developing disease-modifying therapeutics for lysosomal storage disorders with a focus on neurological symptoms.

Biotech

Co-investorsCDP Venture CapitalIreland Strategic Investment FundAdams Street PartnersGenesys CapitalHealthCapOrbiMed+1 more

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

Inozyme

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.